A.I. Spira

机构：Virginia International University, Virginia Cancer Specialists

发表论文 59 篇 · 总被引 162 次 · h-index 7

代表论文

ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. (2025 · Journal of Clinical Oncology · 被引 16)
The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 4)
LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC) (2025 · Annals of Oncology · 被引 3)
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC). (2025 · Journal of Clinical Oncology · 被引 3)
A phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with advanced adenoid cystic carcinoma and colorectal cancer. (2026 · Journal of Clinical Oncology · 被引 2)
NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC). (2026 · Journal of Clinical Oncology · 被引 2)